GlassScriptPhysician profile
Kevin L Powers
NPI 1609875293
$6,062.53
in general payments reported to CMS, 2019-2025
40 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $1,135 · 2021: $1,441 · 2022: $1,084 · 2023: $788 · 2024: $724 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.46 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.98 | 2021-2025 | |
| Novo Nordisk INC | $752.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $642.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $602.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.61 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $516.01 | 2019-2021 | |
| Glaxosmithkline, LLC. | $440.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $335.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.71 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $144.22 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.18 | 2022 | |
| Vivus LLC | $84.10 | 2020-2023 | Qsymia |
| Amgen INC. | $81.69 | 2020-2024 | Otezla, Repatha |
| Genentech USA, INC. | $69.11 | 2019-2021 | |
| Sanofi Pasteur INC. | $67.36 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.